Quantcast

Latest Pyrazoles Stories

2014-06-03 11:22:42

University of Colorado Denver A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...

2014-04-29 16:32:08

- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] EAST HANOVER, N.J., April 29, 2014 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zykadia(TM) (ceritinib, previously known as LDK378) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are...

2014-04-10 12:22:23

DUBLIN, Apr. 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zkcngs/global_and ) has announced the addition of the "Global and Chinese FIPRONIL Industry Report 2014" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The Global and Chinese FIPRONIL Industry Report 2014 is a professional and in-depth study on the current state of the global FIPRONIL industry with a focus on the Chinese situation. The report...

2014-03-28 23:04:00

DeepResearchReports.com offers "2014 Deep Research Report on Global and China FIPRONIL Industry" and "2014 Deep Research Report on Global and China Azoxystrobin Industry" market analysis studies in its store. Dallas, TX (PRWEB) March 28, 2014 These are professional and in-depth research reports on Global and Chinese fipronil industry and azoxystrobin market. The reports introduce basic information on fipronil and azoxystrobin including definition, classification,...

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-02-25 14:34:50

Results Support Need for Combined Testing The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor. The discovery of ALK rearrangement in about 1% to 7%...

2013-10-21 13:15:33

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity,...

2013-10-03 23:22:52

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 03, 2013 PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of...

2013-09-10 23:02:58

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. Aurora, Colo. (PRWEB) September 10, 2013 A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related